Publicación: Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national reg...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez-Lorenzo, M. L. (María Luisa)|||/items/fb6ea26e-f740-4675-9b3d-5ecc547cdd88, Jiménez-Fonseca, P. (Paula)|||/items/b4a18f79-34f0-4736-8966-255e938b871a, Carmona-Bayonas, A. (Alberto)|||/items/eb36b079-361e-478f-9dde-dea0d62109a2, Gallego-Plazas, J. (Javier)|||/items/bffc5186-5838-4da6-9c76-145f6354348f, Custodio, A. (Ana)|||/items/48122708-d401-4eab-8a9c-06a55ceaa644, Hernández, R. (Raquel)|||/items/67199cc4-a62c-4a9e-ba19-f7d6ab73cc65, Garrido, M. (Marcelo)|||/items/cf383934-2e5e-449e-8642-5f071a5d2644, García-García, T. (Teresa)|||/items/101f5ba0-98a4-4a05-bf8f-16ca5162cba9, Echavarría, I. (Isabel)|||/items/c6295557-d975-4a6f-957c-cf6023fd7084, Cano, J. M. (Juana María)|||/items/3f58d339-5190-47e2-ac69-3a6023ab0401, Rodríguez-Palomo, A. (Alberto)|||/items/b9b89197-b6a3-4bd0-b7c8-0f40c41d757c, Mangas, M. (Monserrat)|||/items/227a81b8-0bde-41fe-9ea2-b722b327d444, Macías-Declara, I. (Ismael)|||/items/98e7a117-47b7-4096-b209-c9cae9c65963, Ramchandani, A. (Avinash)|||/items/1590ce7c-245f-400a-aadb-b854153b5c96, Visa, L. (Laura)|||/items/b9eef53d-91de-4d90-b6d7-3aaaa53e9e19, Viudez, A. (Antonio)|||/items/cdc323b7-efce-4d1e-97d9-713f0789385e, Buxó, E. (Elvira)|||/items/800b8938-72dc-430f-bd00-f58354467f6d, Sanchez-Bayona, R. (Rodrigo)|||/items/87f95f8a-7474-40d8-9ac8-14ee3c1cc6ba, Pimentel, P. (Paola)|||/items/7273217f-b235-451f-9776-0049a88f3bb3, Limón, M. L. (María-Luisa)|||/items/74529aaa-60fe-4ce9-9174-31646e4ef000, Cerdá, P. (Paula)|||/items/f4f7d251-6c22-4396-827b-384cfabcde5e, Álvarez-Llosa, R. (Renata)|||/items/e8ef7500-32df-4d5f-9547-90edddd781a5, Serrano, R. (Raquel)|||/items/e1e9fa40-b5bf-4111-a0db-96febfc4dd96, Felices-Lobera, M. P. (María Pilar)|||/items/7d3b4a1f-b5ca-45e2-ab45-6adacaf3aeed, Alsina, M. (María)|||/items/4831b66e-177d-49b0-bba6-56ad837cf680, Hurtado-Nuño, A. (Alicia)|||/items/fff50024-4215-464e-a01f-e72ef6cf39a5, Gómez-Martin, C. (Carlos)|||/items/907c3b08-cfce-4bbe-9652-155cfc3812a3, Castañón-Álvarez, E. (Eduardo)|||/items/6ef1df2b-d729-4ca8-af2e-dd81758ddd7a
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/68881
Acceso en línea:https://hdl.handle.net/10171/68881
Access Level:acceso abierto
Palabra clave:Trastuzumab
Stomach Neoplasms
Spain
Receptor, ErbB-2
Proportional Hazards Models
Prognosis
Middle Aged
Male
Kaplan-Meier Estimate
Humans
Female
Biomarkers, Tumor
Antineoplastic Combined Chemotherapy Protocols
Aged, 80 and over
Adult
Gastric cancer
HER2 testing
Personalized medicine
Quality of care
Descripción
Sumario:Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of HER2 testing on patient prognosis in a national registry of AGC. This Spanish National Cancer Registry includes cases who were consecutively recruited at 28 centers from January 2008 to January 2016. The effect of missing HER2 status was assessed using stratified Cox proportional hazards (PH) regression. The rate of HER2 testing increased steadily over time, from 58.3 % in 2008 to 92.9 % in 2016. HER2 was positive in 194 tumors (21.3 %). In the stratified Cox PH regression, each 1 % increase in patients who were not tested for HER2 at the institutions was associated with an approximately 0.3 % increase in the risk of death: hazard ratio, 1.0035 (CI 95 %, 1.001-1.005), P = 0.0019. Median OS was significantly lower at institutions with the highest proportions of patients who were not tested for HER2. Patients treated at centers that took longer to implement HER2 testing exhibited worse clinical outcomes. The speed of implementation behaves as a quality-of-care indicator. Reviewed guidelines on HER2 testing should be used to achieve this goal in a timely manner.

Similares en LA Referencia